Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

Jennifer Woyach, MD
Published: Wednesday, Dec 07, 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
The study includes 4 cohorts of patients – including patients with relapse/refractory CLL, treatment naïve CLL, richter’s transformation, and patients who have received treatment with ibrutinib (Imbruvica) and have developed mutations that will render them resistant to ibrutinib without having clinical progression, Woyach says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication